Product Candidates Overview

Mesoblast has applied its proprietary cell technology platform, which is based on mesenchymal lineage adult stem cells, to build what it believes is the most advanced allogeneic mesenchymal lineage cell-based product portfolio in the industry. This technology has the potential to address multiple conditions with significant unmet medical needs.

The Company’s ‘off-the-shelf’ products are allogeneic - meaning cells from a single donor can be used in different recipients without the need for matching.

Mesoblast has filed a rolling Biologics License Application (BLA) with the FDA for RYONCIL™ (remestemcel-L) in the treatment of pediatric steroid-refractory acute graft versus host disease. Remestemcel-L is also being developed for other rare diseases.

The Company’s Phase 3 product candidates are REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease, both major diseases with high unmet medical needs.

Additionally, Mesoblast has a strong emerging pipeline of product candidates.

Diverse Portfolio of Advanced Cellular Medicines: